About the Conference

The fields of liquid biopsy and immuno-oncology are coming together as the pace of discovery of new targets and innovativetreatments are ramping up and requiring novel biomarkers to predict which patients will be respond to treatment, minimize toxicity and monitor therapy. A wide range of new circulating biomarkers are being discovered and they will be vetted for their suitability for assays and use in the clinical setting. Immunotherapy advances include an expanding array of T-cell engineering approaches, next generation molecules and companion diagnostics to guide treatment decisions.


Circulating Tumor Cells in Breast Cancers: Current Clinical Validity and Utility

François-Clément BidardFrançois-Clément Bidard, MD, PhD, Professor of Medical Oncology, Institut Curie & Versailles St. Quentin University

Critical Assessment of the Challenges of Using Blood-Based Biomarkers in Prostate Cancer from a Clinical Point of View

Daniel DanilaDaniel C. Danila, MD, Medical Oncology Fellow, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center

Biomarkers to Inform Trial Design and Combinations in Immuno-Oncology

Mazumder_RonRon Mazumder, PhD, MBA, Vice President, Oncology Biomarker Development & Companion Diagnostics, Genentech

The Targeted Agent and Profiling Utilization Registry Study: Rationale, Design and Preliminary Findings

Richard SchilskyRichard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President, CMO, American Society of Clinical Oncology

Treatment of Breast and Gynecologic Cancers with Cancer Immunotherapy

Dupont_JakobJakob Dupont, MD, Vice President, Global Head, Breast & Gynecologic Cancer Development, Genentech

Register Now

Conference Programs